HIV cell-to-cell transmission: Effects on pathogenesis and antiretroviral therapy

Trends in Microbiology

Volumn 23, Issue 5, 2015, Pages 289-295

  Agosto, Luis M ^a,b   Uchil, Pradeep D ^a   Mothes, Walther ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Cell to cell transmission; Human immunodeficiency virus; Virological synapse

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NEVIRAPINE; TENOFOVIR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRIPARTITE MOTIF PROTEIN 5; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CELL DEATH; DNA DAMAGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DEPLETION; MOLECULAR IMAGING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION; VIRUS ISOLATION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSMISSION; ANIMAL; CD4 LYMPHOCYTE COUNT; CELL LINE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PHYSIOLOGY; PROVIRUS; ULTRASTRUCTURE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; PROVIRUSES; VIRUS REPLICATION;

EID: 84937633522     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2015.02.003     Document Type: Review

References (109)

1. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat. Rev. Microbiol. 2008, 6:815-826.
2. Zhong P., et al. Cell-to-cell transmission of viruses. Curr. Opin. Virol. 2013, 3:44-50.
3. Alvarez R.A., et al. Unique features of HIV-1 spread through T cell virological synapses. PLoS Pathog. 2014, 10:e1004513.
4. Chen P., et al. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J. Virol. 2007, 81:12582-12595.
5. Jolly C., et al. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J. Exp. Med. 2004, 199:283-293.
6. Phillips D.M. The role of cell-to-cell transmission in HIV infection. AIDS 1994, 8:719-731.
7. Dimitrov D.S., et al. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 1993, 67:2182-2190.
8. Carr J.M., et al. Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology 1999, 265:319-329.
9. Sourisseau M., et al. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J. Virol. 2007, 81:1000-1012.
10. Zhong P., et al. Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS ONE 2013, 8:e53138.
11. Martin N., et al. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J. Virol. 2010, 84:3516-3527.
12. McDonald D., et al. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003, 300:1295-1297.
13. Vasiliver-Shamis G., et al. Human immunodeficiency virus type 1 envelope gp120-induced partial T-cell receptor signaling creates an F-actin-depleted zone in the virological synapse. J. Virol. 2009, 83:11341-11355.
14. Vasiliver-Shamis G., et al. Human immunodeficiency virus type 1 envelope gp120 induces a stop signal and virological synapse formation in noninfected CD4+ T cells. J. Virol. 2008, 82:9445-9457.
15. Jolly C., et al. Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells. J. Virol. 2007, 81:13916-13921.
16. Rudnicka D., et al. Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple tragets through polysynapses. J. Virol. 2009, 83:6234-6246.
17. Jolly C., et al. The regulated secretory pathway in CD4(+) T cells contributes to human immunodeficiency virus type-1 cell-to-cell spread at the virological synapse. PLoS Pathog. 2011, 7:e1002226.
18. Hubner W., et al. Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science 2009, 323:1743-1747.
19. Llewellyn G.N., et al. Nucleocapsid promotes localization of HIV-1 gag to uropods that participate in virological synapses between T cells. PLoS Pathog. 2010, 6:e1001167.
20. Monel B., et al. HIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through Env-mediated fusion pores. J. Virol. 2012, 86:3924-3933.
21. Li P., et al. Synthesis of human immunodeficiency virus DNA in a cell-to-cell transmission model. AIDS Res. Hum. Retrovir. 1992, 8:253-259.
22. Li P., et al. De novo reverse transcription is a crucial event in cell-to-cell transmission of human immunodeficiency virus. J. Gen. Virol. 1992, 73:955-959.
23. Agosto L.M., et al. Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission. PLoS Pathog. 2014, 10:e1003982.
24. Gupta P., et al. Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody. J. Virol. 1989, 63:2361-2365.
25. Ganesh L., et al. Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J. Virol. 2004, 78:11980-11987.
26. Malbec M., et al. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J. Exp. Med. 2013, 210:2813-2821.
27. Abela I.A., et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 2012, 8:e1002634.
28. Massanella M., et al. Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. AIDS 2009, 23:183-188.
29. McCoy L.E., et al. Neutralisation of HIV-1 cell-cell spread by human and llama antibodies. Retrovirology 2014, 11:83.
30. Coleman C.M., et al. Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef. Retrovirology 2011, 8:26.
31. Jolly C., et al. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J. Virol. 2010, 84:12185-12199.
32. Richardson M.W., et al. Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. J. Virol. 2008, 82:11117-11128.
33. Casartelli N., et al. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog. 2010, 6:e1000955.
34. Kuhl B.D., et al. Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology 2010, 7:115.
35. Giese S., et al. Tetherin can restrict cell-free and cell-cell transmission of HIV from primary macrophages to T cells. PLoS Pathog. 2014, 10:e1004189.
36. Brandenberg O.F., et al. Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain inverted question marks exceptional capacity for sequence variation. Retrovirology 2014, 11:75.
37. Del Portillo A., et al. Multiploid inheritance of HIV-1 during cell-to-cell infection. J. Virol. 2011, 85:7169-7176.
38. Duncan C.J., et al. High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J. Virol. 2014, 88:2025-2034.
39. Russell R.A., et al. Multiple proviral integration events after virological synapse-mediated HIV-1 spread. Virology 2013, 443:143-149.
40. Gratton S., et al. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:14566-14571.
41. Jung A., et al. Recombination: multiply infected spleen cells in HIV patients. Nature 2002, 418:144.
42. Josefsson L., et al. Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. PLoS Pathog. 2013, 9:e1003432.
43. Josefsson L., et al. Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:11199-11204.
44. Iwasaki A. Innate immune recognition of HIV-1. Immunity 2012, 37:389-398.
45. Holm C.K., et al. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat. Immunol. 2012, 13:737-743.
46. Kane M., et al. Innate immune sensing of retroviral infection via Toll-like receptor 7 occurs upon viral entry. Immunity 2011, 35:135-145.
47. Browne E.P. Toll-like receptor 7 controls the anti-retroviral germinal center response. PLoS Pathog. 2011, 7:e1002293.
48. Gringhuis S.I., et al. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat. Immunol. 2010, 11:419-426.
49. Lepelley A., et al. Innate sensing of HIV-infected cells. PLoS Pathog. 2011, 7:e1001284.
50. Pertel T., et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011, 472:361-365.
51. Ganser-Pornillos B.K., et al. Hexagonal assembly of a restricting TRIM5alpha protein. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:534-539.
52. Solis M., et al. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J. Virol. 2011, 85:1224-1236.
53. Gao D., et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 2013, 341:903-906.
54. Yan N., et al. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 2010, 11:1005-1013.
55. Monroe K.M., et al. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science 2014, 343:428-432.
56. Ryoo J., et al. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat. Med. 2014, 20:936-941.
57. Cooper A., et al. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 2013, 498:376-379.
58. Rasaiyaah J., et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature 2013, 503:402-405.
59. Doitsh G., et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014, 505:509-514.
60. Doitsh G., et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010, 143:789-801.
61. Sigal A., et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011, 477:95-98.
62. Mathez D., et al. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob. Agents Chemother. 1993, 37:2206-2211.
63. Duncan C.J., et al. High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy. AIDS 2013, 27:2201-2206.
64. Permanyer M., et al. Antiretroviral agents effectively block HIV replication after cell-to-cell transfer. J. Virol. 2012, 86:8773-8780.
65. Titanji B.K., et al. Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells. Retrovirology 2013, 10:161.
66. Gulick R.M., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 1997, 337:734-739.
67. Perelson A.S., et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
68. Hammer S.M., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 1997, 337:725-733.
69. Laskey S.B., et al. A mechanistic theory to explain the efficacy of antiretroviral therapy. Nat. Rev. Microbiol. 2014, 12:772-780.
70. Patterson K.B., et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS 2013, 27:1413-1419.
71. Patterson K.B., et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci. Transl. Med. 2011, 3:112re114.
72. Fletcher C.V., et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:2307-2312.
73. Evering T.H., et al. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog. 2012, 8:e1002506.
74. Josefsson L., et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E4987-E4996.
75. Guihot A., et al. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol. 2011, 32:131-137.
76. Meyer P.R., et al. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 1999, 4:35-43.
77. Meyer P.R., et al. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:13471-13476.
78. Arion D., et al. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998, 37:15908-15917.
79. Acosta-Hoyos A.J., et al. The role of nucleotide excision by reverse transcriptase in HIV drug resistance. Viruses 2010, 2:372-394.
80. Boyer P.L., et al. The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J. Virol. 2002, 76:3248-3256.
81. Gotte M., et al. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. 2000, 74:3579-3585.
82. Feng J.Y., et al. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 2009, 6:44.
83. Frankel F.A., et al. Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRTI-associated mutations by apricitabine triphosphate. Antivir. Chem. Chemother. 2007, 18:93-101.
84. Michailidis E., et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J. Biol. Chem. 2014, 289:24533-24548.
85. Wong A. The HIV pipeline. Nat. Rev. Drug. Discov. 2014, 13:649-650.
86. Jurado K.A., et al. Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:8690-8695.
87. Komarova N.L., et al. Synaptic transmission and the susceptibility of HIV infection to anti-viral drugs. Sci. Rep. 2013, 3:2103.
88. Shen L., et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 2008, 14:762-766.
89. Durham N.D., et al. Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail. J. Virol. 2012, 86:7484-7495.
90. Dale B.M., et al. Cell-to-cell transfer of HIV-1 via virological synapses leads to endosomal virion maturation that activates viral membrane fusion. Cell Host Microbe 2011, 10:551-562.
91. Sloan R.D., et al. Productive entry of HIV-1 during cell-to-cell transmission via dynamin-dependent endocytosis. J. Virol. 2013, 87:8110-8123.
92. Swartz T.H., et al. P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection. J. Virol. 2014, 88:11504-11515.
93. Costantino C.M., et al. Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PLoS ONE 2012, 7:e33961.
94. Sewald X., et al. In vivo imaging of virological synapses. Nat. Commun. 2012, 3:1320.
95. Murooka T.T., et al. HIV-infected T cells are migratory vehicles for viral dissemination. Nature 2012, 490:283-287.
96. Miyauchi K., et al. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009, 137:433-444.
97. Herold N., et al. HIV-1 entry in SupT1-R5, CEM-ss and primary CD4+ T-cells occurs at the plasma membrane and does not require endocytosis. J. Virol. 2014, 88:13956-13970.
98. Platt E.J., et al. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms. J. Virol. 2014, 88:4304-4318.
99. van Wilgenburg B., et al. The productive entry pathway of HIV-1 in macrophages is dependent on endocytosis through lipid rafts containing CD4. PLoS ONE 2014, 9:e86071.
100. Bosch B., et al. A clathrin-dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell-T cell transmission. Antivir. Res. 2008, 80:185-193.
101. Blanco J., et al. High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells. J. Biol. Chem. 2004, 279:51305-51314.
102. Heil F., et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
103. Chattergoon M.A., et al. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog. 2014, 10:e1004082.
104. Melikyan G.B. HIV entry: a game of hide-and-fuse?. Curr. Opin. Virol. 2014, 4:1-7.
105. Stremlau M., et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:5514-5519.
106. Refsland E.W., et al. The APOBEC3 family of retroelement restriction factors. Curr. Top. Microbiol. Immunol. 2013, 371:1-27.
107. Sze A., et al. SAMHD1 host restriction factor: a link with innate immune sensing of retrovirus infection. J. Mol. Biol. 2013, 425:4981-4994.
108. Goujon C., et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013, 502:559-562.
109. Kane M., et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 2013, 502:563-566.